Azithromycin
Severe
Database
Drug interaction classified as: synergy, absorption
Source: DDInter
Drug reference
relugolix
nonpeptide GnRH antagonist · Antineoplastic agent
nonpeptide GnRH antagonistAntineoplastic agentATC null
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
X
FDA category + note
Top interactionssee all 12 →
- AzithromycinSevereDatabaseDDInter
- BedaquilineSevereDatabaseDDInter
- CabozantinibSevereDatabaseDDInter
- CapmatinibSevereDatabaseDDInter
Mechanism
Relugolix is an orally available, nonpeptide GnRH antagonist that antagonizes the GnRH receptor by reversible competition with GnRH. This results in rapid reduction in LH and FSH secretion from the pituitary and concomitant loss of testosterone production to castrate levels from the testes. It avoids the initial testosterone surge seen with GnRH agonists and is more effective at suppressing FSH.
Indications
Treatment of prostate cancer (FDA-approved)
Dosing
- Adult
- Initial oral loading dose (360 mg), followed by one tablet (120 mg) daily.
Pharmacokinetics
Onset
Steady-state levels are achieved after 7 days.
Bioavailability
Food can diminish oral bioavailability by 50%.
Metabolism
Predominant metabolizer is CYP3A4. Absorption and distribution are influenced by the efflux transporter P-glycoprotein (Pgp).
Excretion
Metabolites are excreted mainly in feces.
Contraindications
- Women of childbearing potential (male patients with female partners of reproductive potential should use contraception during and for 2 weeks following the last dose due to reproductive and fetal harm in animal toxicity tests)
Side effects
Common
Hot flushesIncreased blood glucose levelsIncreased triglyceride levelsMusculoskeletal painAnemiaIncreased liver enzymesTirednessConstipationDiarrhea
Serious
- Prolongation of the cardiac QT/QTc interval
- Reproductive and fetal harm (in animal toxicity tests)
Pregnancy & lactation
Pregnancy
X
Drug interactions
Bedaquiline
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cabozantinib
Severe
Database
Drug interaction classified as: synergy, absorption
Source: DDInter
Capmatinib
Severe
Database
Drug interaction classified as: absorption
Source: DDInter
Carbamazepine
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Carvedilol
Severe
Database
Drug interaction classified as: absorption
Source: DDInter
Ceritinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Citalopram
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Clarithromycin
Severe
Database
Drug interaction classified as: synergy, absorption
Source: DDInter
Clozapine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cobicistat
Severe
Database
Drug interaction classified as: absorption
Source: DDInter
Crizotinib
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Ask House about relugolix
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team